ATE451381T1 - Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen - Google Patents
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungenInfo
- Publication number
- ATE451381T1 ATE451381T1 AT06718943T AT06718943T ATE451381T1 AT E451381 T1 ATE451381 T1 AT E451381T1 AT 06718943 T AT06718943 T AT 06718943T AT 06718943 T AT06718943 T AT 06718943T AT E451381 T1 ATE451381 T1 AT E451381T1
- Authority
- AT
- Austria
- Prior art keywords
- prodrugs
- pyrimidinediamine compounds
- methods
- intermediates
- synthesizing
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title abstract 5
- 239000000651 prodrug Substances 0.000 title abstract 5
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64542405P | 2005-01-19 | 2005-01-19 | |
US65462005P | 2005-02-18 | 2005-02-18 | |
PCT/US2006/001945 WO2006078846A1 (en) | 2005-01-19 | 2006-01-19 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE451381T1 true ATE451381T1 (de) | 2009-12-15 |
Family
ID=36295425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06718943T ATE451381T1 (de) | 2005-01-19 | 2006-01-19 | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
Country Status (28)
Country | Link |
---|---|
US (13) | US7449458B2 (de) |
EP (2) | EP2161275A1 (de) |
JP (2) | JP4801096B2 (de) |
KR (1) | KR101278397B1 (de) |
CN (1) | CN101115761B (de) |
AT (1) | ATE451381T1 (de) |
AU (1) | AU2006206458B2 (de) |
BR (1) | BRPI0606318B8 (de) |
CA (1) | CA2591948C (de) |
CY (2) | CY1109888T1 (de) |
DE (1) | DE602006010979D1 (de) |
DK (1) | DK1856135T3 (de) |
ES (1) | ES2337496T3 (de) |
FI (1) | FIC20200014I1 (de) |
HK (1) | HK1108896A1 (de) |
HU (1) | HUS2000011I1 (de) |
IL (1) | IL183890A (de) |
LT (1) | LTC1856135I2 (de) |
LU (1) | LUC00153I2 (de) |
MX (2) | MX2007007189A (de) |
NL (1) | NL301039I2 (de) |
NO (2) | NO339146B1 (de) |
NZ (1) | NZ555947A (de) |
PL (1) | PL1856135T3 (de) |
PT (1) | PT1856135E (de) |
RU (1) | RU2416616C2 (de) |
SI (1) | SI1856135T1 (de) |
WO (1) | WO2006078846A1 (de) |
Families Citing this family (210)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
MXPA05001096A (es) * | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
EP1633758B1 (de) * | 2003-05-15 | 2011-11-23 | Arqule, Inc. | Imidazothiazole und imidazoxazolderivative als inhibitoren von p38 |
KR20120062863A (ko) * | 2003-07-30 | 2012-06-14 | 리겔 파마슈티칼스, 인크. | 자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물 |
JP4812763B2 (ja) | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ, インコーポレイテッド | シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途 |
EP2258704A1 (de) * | 2004-10-19 | 2010-12-08 | ArQule, Inc. | Synthese aus Imidazooxazol- und Imidazothiazol-hemmern der P38-map-kinase |
GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
CA2584295C (en) * | 2004-11-24 | 2014-08-26 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
EP2161275A1 (de) * | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs aus 2,4-Pyrimidindiamin-Verbindungen und ihre Verwendungen |
US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
WO2007027238A2 (en) * | 2005-05-03 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Jak kinase inhibitors and their uses |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
JP2008543855A (ja) | 2005-06-13 | 2008-12-04 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 変形性骨疾患を処置するための方法および組成物 |
DE602005000514T2 (de) * | 2005-06-17 | 2007-10-25 | Magneti Marelli Powertrain S.P.A. | Brennstoffeinspritzventil |
US20090306028A1 (en) * | 2005-10-31 | 2009-12-10 | Payan Donald G | Compositions and methods for treating inflammatory disorders |
US20100041678A1 (en) * | 2005-10-31 | 2010-02-18 | Rigel Pharmaceuticals, Inc. | Compositions and methods for treating inflammatory disorders |
US7713987B2 (en) * | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
DK1984357T3 (da) * | 2006-02-17 | 2014-01-13 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme |
US8962643B2 (en) * | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
WO2007123892A2 (en) * | 2006-04-17 | 2007-11-01 | Arqule Inc. | Raf inhibitors and their uses |
CA2658506C (en) | 2006-07-20 | 2016-01-26 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as fab 1 inhibitors |
CA2673125C (en) | 2006-10-19 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2008061201A1 (en) * | 2006-11-15 | 2008-05-22 | Rigel Pharmaceuticals, Inc. | Methods for treating renal tumors using 2,4-pyrimidinediamine drug and prodrug compounds |
EP2078026B1 (de) | 2006-11-21 | 2012-01-04 | Rigel Pharmaceuticals, Inc. | Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon |
WO2008118822A1 (en) | 2007-03-23 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US7834024B2 (en) * | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US20090012045A1 (en) * | 2007-06-26 | 2009-01-08 | Rigel Pharmaceuticals, Inc. | Methods of Treating Cell Proliferative Disorders |
CN101903357A (zh) | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | 作为pkc抑制剂的环状胺取代的嘧啶二胺 |
US20090088371A1 (en) * | 2007-08-28 | 2009-04-02 | Rigel Pharmaceuticals, Inc. | Combination therapy with syk kinase inhibitor |
AU2008323938B2 (en) * | 2007-11-07 | 2014-04-10 | Rigel Pharmaceuticals, Inc. | Wet granulation using a water sequestering agent |
NZ587589A (en) * | 2008-02-15 | 2012-10-26 | Rigel Pharmaceuticals Inc | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
RU2490015C2 (ru) * | 2008-02-22 | 2013-08-20 | Райджел Фармасьютикалз, Инк. | Применение 2,4-пиримидиндиаминов для лечения атеросклероза |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
PT2323993E (pt) | 2008-04-16 | 2015-10-12 | Portola Pharm Inc | 2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak |
CN103224497A (zh) | 2008-04-22 | 2013-07-31 | 波托拉医药品公司 | 蛋白激酶抑制剂 |
AU2013205506B2 (en) * | 2008-05-21 | 2016-04-21 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
HUE035029T2 (en) * | 2008-05-21 | 2018-03-28 | Ariad Pharma Inc | Kinase inhibitor phosphorus derivatives |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
EP3549934A1 (de) | 2008-06-27 | 2019-10-09 | Celgene CAR LLC | Heteroarylverbindungen und ihre verwendungen |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
WO2010013158A1 (en) | 2008-07-28 | 2010-02-04 | Pfizer Inc. | Phenanthrenone compounds, compositions and methods |
WO2010027002A1 (ja) * | 2008-09-05 | 2010-03-11 | 塩野義製薬株式会社 | Pi3k阻害活性を有する縮環モルホリン誘導体 |
NZ591615A (en) | 2008-09-18 | 2012-07-27 | Auspex Pharmaceuticals Inc | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
US20100183600A1 (en) * | 2008-12-05 | 2010-07-22 | Arqule, Inc. | RAF Inhibitors and Their Uses |
TW201034675A (en) | 2008-12-18 | 2010-10-01 | Sanofi Aventis | Method for treating macular degeneration |
US8324200B2 (en) | 2009-01-23 | 2012-12-04 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
AR076550A1 (es) | 2009-05-06 | 2011-06-22 | Portola Pharm Inc | Inhibidores de la janus tirosina kinasa (jak) |
UA108077C2 (xx) * | 2009-07-02 | 2015-03-25 | Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну | |
CA2768368A1 (en) | 2009-07-17 | 2011-01-20 | Rigel Pharmaceuticals, Inc. | Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
AU2010281404A1 (en) * | 2009-07-28 | 2012-02-09 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
CA2780777C (en) | 2009-11-20 | 2017-12-05 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
WO2011075560A1 (en) | 2009-12-17 | 2011-06-23 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
SG181803A1 (en) | 2009-12-17 | 2012-07-30 | Merck Sharp & Dohme | Aminopyrimidines as syk inhibitors |
US20110206661A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Trimethoxyphenyl inhibitors of tyrosine kinase |
WO2011130390A1 (en) | 2010-04-13 | 2011-10-20 | Rigel Pharmaceuticals, Inc. | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
DK2598500T3 (da) | 2010-07-28 | 2021-07-26 | Rigel Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen |
BR112013003388A2 (pt) | 2010-08-10 | 2016-07-12 | Celgene Avilomics Res Inc | sal de besilato de um inibidor de btk |
JP5957460B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | 複素環式化合物またはその使用 |
WO2012061303A1 (en) | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
US8796255B2 (en) | 2010-11-10 | 2014-08-05 | Celgene Avilomics Research, Inc | Mutant-selective EGFR inhibitors and uses thereof |
EP2489663A1 (de) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Verbindungen als Syk-Kinasehemmer |
EA201391626A1 (ru) | 2011-05-04 | 2014-03-31 | Ариад Фармасьютикалз, Инк. | Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака |
WO2012154520A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
WO2012154518A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
JP2014513686A (ja) | 2011-05-10 | 2014-06-05 | メルク・シャープ・アンド・ドーム・コーポレーション | Syk阻害薬としてのアミノピリミジン |
UY34072A (es) | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
WO2012167423A1 (en) | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
PL2736487T3 (pl) | 2011-07-28 | 2019-06-28 | Rigel Pharmaceuticals, Inc. | Nowe preparaty (trimetoksyfenyloamino)pirymidynylowe |
US9216173B2 (en) | 2011-10-05 | 2015-12-22 | Merck Sharp & Dohme Corp. | 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
EP2763974B1 (de) | 2011-10-05 | 2016-09-14 | Merck Sharp & Dohme Corp. | Phenylcarboxamidhaltige milztyrosinkinase (syk) hemmer |
US8987456B2 (en) | 2011-10-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
AR088570A1 (es) | 2011-10-28 | 2014-06-18 | Celgene Avilomics Res Inc | Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton |
AU2012340555B2 (en) | 2011-11-23 | 2016-10-20 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
CN104284584B (zh) | 2012-03-15 | 2019-06-04 | 西建卡尔有限责任公司 | 表皮生长因子受体激酶抑制剂的盐 |
WO2013138495A1 (en) | 2012-03-15 | 2013-09-19 | Celgene Avilomics Research, Inc. | Solid forms of an epidermal growth factor receptor kinase inhibitor |
US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
WO2013190384A1 (en) | 2012-06-19 | 2013-12-27 | Affinium Pharmaceuticals, Inc. | Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide |
EP2863914B1 (de) | 2012-06-20 | 2018-10-03 | Merck Sharp & Dohme Corp. | Pyrazolylderivate als syk-hemmer |
EP2863913B1 (de) | 2012-06-20 | 2018-09-12 | Merck Sharp & Dohme Corp. | Imidazolylanaloga als syk-hemmer |
CN102746337B (zh) * | 2012-06-21 | 2014-12-17 | 成都苑东药业有限公司 | 一种2,4-嘧啶二胺类化合物及其制备方法 |
WO2013192098A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2013192088A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
EP2884982B1 (de) | 2012-08-20 | 2017-09-20 | Merck Sharp & Dohme Corp. | Substituierte phenyl-milz-tyrosinkinaseinhibitoren |
IN2015DN01662A (de) | 2012-09-18 | 2015-07-03 | Auspex Pharmaceuticals Inc | |
US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
US9586931B2 (en) | 2012-09-28 | 2017-03-07 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as Syk inhibitors |
EP2916837A4 (de) * | 2012-11-07 | 2016-07-20 | Merck Sharp & Dohme | Prodrug-bipyridylaminopyridine als syk-hemmer |
EP2931281B1 (de) | 2012-12-12 | 2018-01-17 | Merck Sharp & Dohme Corp. | Aminopyridinhaltige milz-tyrosinkinase-hemmer |
WO2014100314A1 (en) | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
EP2988744A4 (de) | 2013-04-26 | 2016-11-02 | Merck Sharp & Dohme | Thiazolsubstituierte aminoheteroaryle als milztyrosinkinasehemmer |
WO2014176216A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
EA201791466A1 (ru) | 2013-12-03 | 2017-11-30 | Оспекс Фармасьютикалз, Инк. | Способы получения соединений бензохинолина |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
WO2015095445A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
US9670196B2 (en) | 2013-12-20 | 2017-06-06 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors |
WO2015094997A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
JP6522005B2 (ja) * | 2013-12-20 | 2019-05-29 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 薬学的方法および中間体 |
ES2921874T3 (es) | 2014-02-28 | 2022-09-01 | Nimbus Lakshmi Inc | Inhibidores de TYK2 y usos de los mismos |
WO2015138273A1 (en) | 2014-03-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
SG11201607525UA (en) * | 2014-03-24 | 2016-10-28 | Ab Science | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors |
CN117088931A (zh) | 2014-08-12 | 2023-11-21 | 莫纳什大学 | 定向淋巴的前药 |
EP3179858B1 (de) | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Formen und zusammensetzungen eines erk-inhibitors |
US20160251376A1 (en) | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
PL3265085T3 (pl) | 2015-03-06 | 2022-11-07 | Auspex Pharmaceuticals, Inc. | Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi |
US20180296579A1 (en) | 2015-04-24 | 2018-10-18 | Rigel Pharmaceuticals, Inc. | Methods of treating ibrutinib-resistant disease |
WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017040757A1 (en) | 2015-09-02 | 2017-03-09 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
WO2017041139A1 (en) | 2015-09-08 | 2017-03-16 | Monash University | Lymph directing prodrugs |
WO2017044720A1 (en) | 2015-09-11 | 2017-03-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
PT3364958T (pt) | 2015-10-23 | 2023-04-10 | Navitor Pharm Inc | Moduladores de interação sestrina-gator2 e utilizações dos mesmos |
WO2017106352A1 (en) | 2015-12-14 | 2017-06-22 | Raze Therapeutics, Inc. | Caffeine inhibitors of mthfd2 and uses thereof |
MX2018010254A (es) | 2016-02-26 | 2018-12-19 | Debiopharm Int Sa | Medicamento para el tratamiento de infecciones de pie diabetico. |
PL3426244T3 (pl) | 2016-03-09 | 2023-09-25 | Raze Therapeutics, Inc. | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania |
US10954220B2 (en) | 2016-03-09 | 2021-03-23 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス4 ファーマシューティカルズ, インコーポレイテッド | 癌を処置する方法 |
CA3027500A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
CA3027495A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
CA3039202A1 (en) | 2016-10-14 | 2018-04-19 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
WO2018075937A1 (en) | 2016-10-21 | 2018-04-26 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
US10414727B2 (en) | 2016-11-08 | 2019-09-17 | Navitor Pharmaceuticals, Inc. | Phenyl amino piperidine mTORC inhibitors and uses thereof |
JP2019535839A (ja) | 2016-11-29 | 2019-12-12 | ピュアテック ヘルス エルエルシー | 治療剤の送達のためのエクソソーム |
US11091451B2 (en) | 2016-12-05 | 2021-08-17 | Raze Therapeutics, Inc. | SHMT inhibitors and uses thereof |
CN110603261A (zh) | 2016-12-23 | 2019-12-20 | 拜斯科阿迪有限公司 | 具有新型键结构的肽衍生物 |
US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
AR111233A1 (es) | 2017-03-08 | 2019-06-19 | Nimbus Lakshmi Inc | Inhibidores de tyk2, usos y métodos para la producción de los mismos |
EP3375784A1 (de) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aza-dihydro-acridonderivate |
EP3375778A1 (de) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidinderivate |
WO2018191146A1 (en) | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
CN116370448A (zh) | 2017-04-26 | 2023-07-04 | 纳维托制药有限公司 | Sestrin-gator2相互作用的调节剂及其用途 |
US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
CN111032678A (zh) | 2017-06-26 | 2020-04-17 | 拜西克尔德有限公司 | 具有可检测部分的双环肽配体和其用途 |
CN117946115A (zh) | 2017-07-28 | 2024-04-30 | 武田药品工业株式会社 | Tyk2抑制剂与其用途 |
EP3668550A1 (de) | 2017-08-14 | 2020-06-24 | Bicyclerd Limited | Bicyclische peptidligand-prr-a-konjugate und deren verwendung |
US20200291096A1 (en) | 2017-08-14 | 2020-09-17 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
WO2019046491A1 (en) | 2017-08-29 | 2019-03-07 | Ariya Therapeutics, Inc. | LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM |
AU2018338314A1 (en) | 2017-09-22 | 2020-04-09 | Kymera Therapeutics, Inc | Protein degraders and uses thereof |
EP3684366A4 (de) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | Crbn-liganden und verwendungen davon |
EP3727362A4 (de) | 2017-12-19 | 2021-10-06 | PureTech LYT, Inc. | Lipidprodrugs von mycophenolsäure und ihre verwendungen |
US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
JP2021508703A (ja) | 2017-12-26 | 2021-03-11 | カイメラ セラピューティクス, インコーポレイテッド | Irak分解剤およびそれらの使用 |
EP3737666A4 (de) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Proteinabbaumittel und verwendungen davon |
EP3737675A4 (de) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn-liganden und verwendungen davon |
BR112020015328A2 (pt) | 2018-01-29 | 2020-12-08 | Merck Patent Gmbh | Inibidores de gcn2 e usos dos mesmos |
CA3089769A1 (en) | 2018-01-29 | 2019-08-01 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
KR20200140262A (ko) | 2018-02-27 | 2020-12-15 | 아텍스 바이오파마 인코포레이티드 | Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체 |
ES2969982T3 (es) | 2018-04-24 | 2024-05-23 | Vertex Pharma | Compuestos de pteridinona y usos de los mismos |
IL278142B2 (en) | 2018-04-24 | 2023-11-01 | Merck Patent Gmbh | Antiproliferative compounds and their uses |
WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
EP3817748A4 (de) | 2018-07-06 | 2022-08-24 | Kymera Therapeutics, Inc. | Tricyclische crbn-liganden und verwendungen davon |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
EP3846793B1 (de) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e-inhibitoren und verwendungen davon |
AU2019360941A1 (en) | 2018-10-15 | 2021-04-29 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
CN113164414A (zh) | 2018-10-24 | 2021-07-23 | 纳维托制药有限公司 | 多晶型化合物和其用途 |
US20220000880A1 (en) | 2018-11-01 | 2022-01-06 | Rigel Pharmaceuticals, Inc. | Method and composition embodiments for treating acute myeloid leukemia |
SG11202105424PA (en) | 2018-11-30 | 2021-06-29 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
WO2020112937A1 (en) | 2018-11-30 | 2020-06-04 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
EP3670659A1 (de) | 2018-12-20 | 2020-06-24 | Abivax | Biomarker und verwendungen bei der behandlung von viralen infektionen, entzündlichen oder krebserkrankungen |
JP2022518505A (ja) | 2019-01-23 | 2022-03-15 | ニンバス ラクシュミ, インコーポレイテッド | Tyk2阻害剤およびその使用 |
WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
WO2020201753A1 (en) | 2019-04-02 | 2020-10-08 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
SG11202110829YA (en) | 2019-04-05 | 2021-10-28 | Kymera Therapeutics Inc | Stat degraders and uses thereof |
MX2021014441A (es) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. |
TW202110485A (zh) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
BR112022001896A2 (pt) | 2019-08-14 | 2022-06-21 | Rigel Pharmaceuticals Inc | Método para bloquear ou atenuar síndrome de liberação de citocinas |
EP4028385A4 (de) | 2019-09-11 | 2023-11-08 | Vincere Biosciences, Inc. | Usp30-inhibitoren und verwendungen davon |
CA3150108A1 (en) | 2019-09-13 | 2021-03-18 | Neelu Kaila | HPK1 ANTAGONISTS AND THEIR USES |
US11723890B2 (en) | 2019-11-01 | 2023-08-15 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
TW202134234A (zh) | 2019-12-05 | 2021-09-16 | 美商奈維特製藥公司 | 雷帕黴素類似物及其用途 |
IL293917A (en) | 2019-12-17 | 2022-08-01 | Kymera Therapeutics Inc | Iraq joints and their uses |
EP4076524A4 (de) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | Irak-degrader und verwendungen davon |
WO2021133920A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
CA3166908A1 (en) | 2020-02-05 | 2021-08-12 | Daniel Kenneth BONNER | Lipid prodrugs of neurosteroids |
CA3170411A1 (en) | 2020-03-03 | 2021-09-10 | Christopher L. Vandeusen | Eif4e inhibitors and uses thereof |
CN115776887A (zh) | 2020-03-19 | 2023-03-10 | 凯麦拉医疗公司 | Mdm2降解剂和其用途 |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
KR20230074721A (ko) | 2020-08-17 | 2023-05-31 | 바이사이클티엑스 리미티드 | Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도 |
KR20230131189A (ko) | 2020-12-02 | 2023-09-12 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
JP2024505571A (ja) | 2021-02-02 | 2024-02-06 | リミナル・バイオサイエンシーズ・リミテッド | Gpr84アンタゴニストおよびその使用 |
WO2022167445A1 (en) | 2021-02-02 | 2022-08-11 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
IL304905A (en) | 2021-02-15 | 2023-10-01 | Kymera Therapeutics Inc | IRAK4 joints and their uses |
JP2024509192A (ja) | 2021-03-05 | 2024-02-29 | ニンバス サターン, インコーポレイテッド | Hpk1アンタゴニスト及びその使用 |
KR20230172548A (ko) | 2021-04-16 | 2023-12-22 | 이케나 온콜로지, 인코포레이티드 | Mek 억제제 및 이의 용도 |
CN113624665A (zh) * | 2021-07-30 | 2021-11-09 | 中国药科大学 | 一种抗肿瘤候选化合物在治疗结直肠癌药物中的应用及测定方法 |
US20230134932A1 (en) | 2021-08-25 | 2023-05-04 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
AU2022334296A1 (en) | 2021-08-25 | 2024-03-07 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Mek抑制劑及其用途 |
WO2024028363A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
WO2024028365A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Substituted pyridone gpr84 antagonists and uses thereof |
Family Cites Families (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1029650B (de) | 1954-03-15 | 1958-05-08 | Franz Litzka | Zusatzeinrichtung fuer Schneidmotoren |
EP0139613A1 (de) | 1983-08-29 | 1985-05-02 | Ciba-Geigy Ag | N-(2-Nitrophenyl)-4-aminopyrimidin-Derivate, deren Herstellung und Verwendung |
DE3618353A1 (de) | 1986-05-31 | 1987-12-03 | Hoechst Ag | Schaedlingsbekaempfungsmittel auf der basis von aminopyrimidin-derivaten sowie neue aminopyrimidin-verbindungen |
JPS6312485A (ja) | 1986-06-25 | 1988-01-19 | 日立米沢電子株式会社 | トレ− |
IE63502B1 (en) | 1989-04-21 | 1995-05-03 | Zeneca Ltd | Aminopyrimidine derivatives useful for treating cardiovascular disorders |
JPH03127790A (ja) | 1989-10-11 | 1991-05-30 | Morishita Pharmaceut Co Ltd | N―(1h―テトラゾール―5―イル)―2―アニリノ―5―ピリミジンカルボキシアミド類及びその合成中間体 |
TW224941B (de) | 1989-11-08 | 1994-06-11 | Yamanouchi Pharma Co Ltd | |
GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
DE4029650A1 (de) | 1990-09-19 | 1992-03-26 | Hoechst Ag | 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide |
US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
US5430148A (en) * | 1992-03-31 | 1995-07-04 | Agouron Pharmaceuticals, Inc. | Antiproliferative quinazolines |
CA2174080A1 (en) | 1993-10-12 | 1995-04-20 | Paul Edward Aldrich | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
IL112290A (en) | 1994-01-12 | 1999-01-26 | Novartis Ag | Transformed aryl and the troiryl pyrimidines and herbicides containing them |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
US6004985A (en) | 1996-10-09 | 1999-12-21 | Berlex Laboratories, Inc. | Thio acid derived monocylic N-heterocyclics as anticoagulants |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
US6093820A (en) * | 1997-10-02 | 2000-07-25 | Taro Pharmaceutical Industries Ltd. | Method and reagents for N-alkylating ureides |
GB9723859D0 (en) | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Compound,composition and use |
DE69839735D1 (de) | 1997-12-15 | 2008-08-28 | Astellas Pharma Inc | Pyrimidin-5-carboxamid-derivate |
US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
KR20010033811A (ko) | 1997-12-31 | 2001-04-25 | 토마스 안 빅토리아 | 2차 및 3차 아민을 함유하는 약제의 물에 용해가능한프로드럭 및 그것의 제조방법 |
IL137922A0 (en) | 1998-02-17 | 2001-10-31 | Tularik Inc | Anti-viral pyrimidine derivatives |
ID26291A (id) | 1998-03-27 | 2000-12-14 | Janssen Pharmaceutica Nv | Turunan-turunan pirimidina penghambat hiv |
BRPI9909191B8 (pt) | 1998-03-27 | 2021-07-06 | Janssen Pharmaceutica Nv | derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende |
ES2274634T3 (es) | 1998-08-29 | 2007-05-16 | Astrazeneca Ab | Compuestos de pirimidina. |
DE19851421A1 (de) | 1998-11-07 | 2000-05-11 | Boehringer Ingelheim Pharma | Neue Pyrimidine, deren Herstellung und Verwendung |
OA11674A (en) | 1998-11-10 | 2005-01-12 | Janssen Pharmaceutica Nv | HIV Replication inhibiting pyrimidines. |
US6127376A (en) | 1998-12-04 | 2000-10-03 | Berlex Laboratories, Inc. | Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
DE19917785A1 (de) | 1999-04-20 | 2000-10-26 | Bayer Ag | 2,4-Diamino-pyrimidin-Derivate |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
DE19945982A1 (de) | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
EA005423B1 (ru) | 1999-09-24 | 2005-02-24 | Янссен Фармацевтика Н.В. | Противовирусные композиции |
WO2001023389A2 (en) | 1999-09-30 | 2001-04-05 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
WO2001030782A2 (en) | 1999-10-29 | 2001-05-03 | Syngenta Participations Ag | Novel herbicides |
US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
JP2003519143A (ja) | 1999-12-28 | 2003-06-17 | ファーマコピーア,インコーポレーティッド | ピリミジン及びトリアジン系キナーゼ阻害剤 |
US6362172B2 (en) | 2000-01-20 | 2002-03-26 | Bristol-Myers Squibb Company | Water soluble prodrugs of azole compounds |
CN1429222A (zh) | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | 激酶抑制剂 |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US6525051B2 (en) | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
US6818649B2 (en) * | 2000-04-27 | 2004-11-16 | Basilea Pharmaceutica Ag | Chromenylmethyl pyrimidinediamines as antibacterial agents |
AU782948B2 (en) | 2000-05-08 | 2005-09-15 | Janssen Pharmaceutica N.V. | Prodrugs of HIV replication inhibiting pyrimidines |
EP1282606B1 (de) | 2000-05-08 | 2015-04-22 | Janssen Pharmaceutica NV | Hiv replications hemmende pyrimidinen und triazinen |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
CA2422367C (en) | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6448401B1 (en) * | 2000-11-20 | 2002-09-10 | Bristol-Myers Squibb Company | Process for water soluble azole compounds |
KR100947185B1 (ko) | 2000-12-21 | 2010-03-15 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물 |
ES2324981T3 (es) | 2000-12-21 | 2009-08-21 | Smithkline Beecham Corporation | Pirimidinaminas como moduladores de la angiogenesis. |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
EP1423388B1 (de) | 2001-02-20 | 2008-12-03 | AstraZeneca AB | 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen |
AU2002312933B2 (en) | 2001-05-29 | 2007-12-06 | Schering Ag | CDK inhibiting pyrimidines, production thereof and their use as medicaments |
ATE432929T1 (de) | 2001-06-15 | 2009-06-15 | Vertex Pharma | 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer |
CA2450934A1 (en) | 2001-06-19 | 2002-12-27 | Marco Dodier | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
US6878697B2 (en) | 2001-06-21 | 2005-04-12 | Ariad Pharmaceuticals, Inc. | Phenylamino-pyrimidines and uses thereof |
US20030139435A1 (en) | 2001-06-26 | 2003-07-24 | Gulzar Ahmed | N-heterocyclic inhibitors of TNF-alpha expression |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003026665A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
PT1438053E (pt) | 2001-10-17 | 2008-09-25 | Boehringer Ingelheim Int | Derivados de pirimidina, medicamento contendo estes compostos, sua utilização e processo para a sua preparação |
WO2003032994A2 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
JP2003127790A (ja) | 2001-10-25 | 2003-05-08 | Nippon Soken Inc | メータ装置 |
IL162210A0 (en) | 2001-11-28 | 2005-11-20 | Btg Int Ltd | Preventives or remedies for alzheimer's disease oramyloid protein fibrosis inhibitors containing ni trogen-containing heteroaryl |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
AU2002367172A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
JP4469179B2 (ja) | 2002-01-23 | 2010-05-26 | バイエル ファーマセチカル コーポレーション | Rhoキナーゼ阻害剤としてのピリミジン誘導体 |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
MXPA04007637A (es) | 2002-02-08 | 2004-11-10 | Smithkline Beecham Corp | Compuestos de pirimidina. |
ES2290479T3 (es) | 2002-03-01 | 2008-02-16 | Smithkline Beecham Corporation | Diamino-pirimidinas y su uso como inhibidores de la angiogenesis. |
US7288547B2 (en) | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
JP2005526765A (ja) | 2002-03-11 | 2005-09-08 | シエーリング アクチエンゲゼルシャフト | Cdk−阻害性2−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用 |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
KR100951499B1 (ko) | 2002-03-20 | 2010-04-07 | 브리스톨-마이어스 스큅 컴퍼니 | 플루오로옥신돌의 포스페이트 전구약물 |
AU2003231231A1 (en) | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
WO2004039359A2 (en) | 2002-05-06 | 2004-05-13 | Bayer Pharmaceuticals Corporation | Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders |
AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
PL374023A1 (en) | 2002-05-30 | 2005-09-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of jak and cdk2 protein kinases |
AU2003276125B2 (en) | 2002-06-17 | 2007-05-17 | Smithkline Beecham Corporation | Chemical process |
US7449456B2 (en) | 2002-06-28 | 2008-11-11 | Astellas Pharma, Inc. | Diaminopyrimidinecarboxamide derivative |
MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
AU2003249539A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
US7304071B2 (en) | 2002-08-14 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
AU2003286876A1 (en) | 2002-11-01 | 2004-06-07 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
WO2004041810A1 (en) | 2002-11-05 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of jak and other protein kinases |
MXPA05005547A (es) | 2002-11-28 | 2005-07-26 | Schering Ag | Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos. |
AU2002350719A1 (en) | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
AU2003289330A1 (en) | 2002-12-13 | 2004-07-09 | Kyowa Hakko Kogyo Co., Ltd. | Preventives and/or remedies for central diseases |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
ES2598404T3 (es) | 2003-02-07 | 2017-01-27 | Janssen Pharmaceutica Nv | Derivados de pirimidina para la prevención de infección por el VIH |
CL2004000303A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
ES2325440T3 (es) | 2003-02-20 | 2009-09-04 | Smithkline Beecham Corporation | Compuestos de pirimidina. |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
CA2524221A1 (en) | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Substituted heteroaryls as inhibitors of protein tyrosine phosphatases |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
EP1651595A2 (de) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitinligaseinhibitoren |
CA2533397A1 (en) | 2003-07-22 | 2005-02-03 | Neurogen Corporation | Substituted pyridin-2-ylamine analogues |
US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
BRPI0412347A (pt) | 2003-07-30 | 2006-09-05 | Cyclacel Ltd | 2-aminofenil-4-fenilpiridinas como inibidores de quinase |
KR20120062863A (ko) | 2003-07-30 | 2012-06-14 | 리겔 파마슈티칼스, 인크. | 자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물 |
DE602004032446D1 (de) | 2003-08-07 | 2011-06-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
CA2533320A1 (en) | 2003-08-15 | 2006-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
EP1663992A1 (de) | 2003-09-18 | 2006-06-07 | Novartis AG | 2,4-di (phenylamino) pyrimidine, die sich zur behandlung von proliferativen erkrankungen eignen |
DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
TW200529849A (en) | 2003-11-28 | 2005-09-16 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
MY141255A (en) | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
US7511137B2 (en) | 2003-12-19 | 2009-03-31 | Rigel Pharmaceuticals, Inc. | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
US7745625B2 (en) * | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
JP4812763B2 (ja) | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ, インコーポレイテッド | シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途 |
US20060047135A1 (en) * | 2004-08-30 | 2006-03-02 | Chadwick Scott T | Process for preparing chloromethyl di-tert-butylphosphate |
US20060058525A1 (en) | 2004-09-01 | 2006-03-16 | Rajinder Singh | Synthesis of 2,4-pyrimidinediamine compounds |
EP1794134A1 (de) | 2004-09-29 | 2007-06-13 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel |
CA2584808A1 (en) | 2004-10-29 | 2006-05-11 | Rigel Pharmaceuticals, Inc. | Substituted pyridines with activity on syk kinase |
CA2584295C (en) | 2004-11-24 | 2014-08-26 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
US7442716B2 (en) | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
WO2006074057A2 (en) | 2004-12-30 | 2006-07-13 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
EP2161275A1 (de) * | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs aus 2,4-Pyrimidindiamin-Verbindungen und ihre Verwendungen |
WO2007027238A2 (en) | 2005-05-03 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Jak kinase inhibitors and their uses |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
JP2008543855A (ja) | 2005-06-13 | 2008-12-04 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 変形性骨疾患を処置するための方法および組成物 |
AU2006268531A1 (en) | 2005-07-11 | 2007-01-18 | Sanofi-Aventis | Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as IKK inhibitors |
CA2616512A1 (en) | 2005-07-28 | 2007-02-08 | Intervet International B.V. | Novel benzimidazole (thio) carbamates with antiparasitic activity and the synthesis thereof |
WO2007032263A1 (ja) | 2005-09-13 | 2007-03-22 | Eisai R & D Management Co., Ltd. | 安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物およびその製造方法 |
CA2627242A1 (en) | 2005-10-31 | 2007-05-10 | Rigel Pharmaceuticals, Inc. | Compositions and methods for treating inflammatory disorders |
US7508791B2 (en) | 2005-10-31 | 2009-03-24 | Kyocera Corporation | Wireless communication coding and transmission systems and methods |
US7713987B2 (en) | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
TW200736232A (en) | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
WO2007085540A1 (en) | 2006-01-27 | 2007-08-02 | Glaxo Group Limited | 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives |
DK1984357T3 (da) | 2006-02-17 | 2014-01-13 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme |
US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US7631707B2 (en) * | 2006-03-29 | 2009-12-15 | Cyrus Solutions Corporation | Shape memory alloy actuated steerable drilling tool |
WO2007124589A1 (en) | 2006-05-02 | 2007-11-08 | Merck Frosst Canada Ltd. | Methods for treating or preventing neoplasias |
US7776855B2 (en) | 2006-07-27 | 2010-08-17 | Janssen Pharmaceutica N.V. | Antimicrobial oxazolidinone prodrugs |
CA2673125C (en) | 2006-10-19 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2008118822A1 (en) | 2007-03-23 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US7834024B2 (en) | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US9815606B2 (en) | 2015-04-29 | 2017-11-14 | Barton Group, Inc. | Flexible stand-up pouch container for flowable products |
-
2006
- 2006-01-19 EP EP09015170A patent/EP2161275A1/de not_active Withdrawn
- 2006-01-19 WO PCT/US2006/001945 patent/WO2006078846A1/en active Application Filing
- 2006-01-19 EP EP06718943A patent/EP1856135B1/de active Active
- 2006-01-19 PL PL06718943T patent/PL1856135T3/pl unknown
- 2006-01-19 NZ NZ555947A patent/NZ555947A/en unknown
- 2006-01-19 US US11/337,049 patent/US7449458B2/en active Active
- 2006-01-19 SI SI200630571T patent/SI1856135T1/sl unknown
- 2006-01-19 JP JP2007552272A patent/JP4801096B2/ja active Active
- 2006-01-19 KR KR1020077018898A patent/KR101278397B1/ko active IP Right Grant
- 2006-01-19 DE DE602006010979T patent/DE602006010979D1/de active Active
- 2006-01-19 RU RU2007131430/04A patent/RU2416616C2/ru active
- 2006-01-19 AU AU2006206458A patent/AU2006206458B2/en active Active
- 2006-01-19 BR BRPI0606318A patent/BRPI0606318B8/pt active IP Right Grant
- 2006-01-19 MX MX2007007189A patent/MX2007007189A/es active IP Right Grant
- 2006-01-19 CA CA2591948A patent/CA2591948C/en active Active
- 2006-01-19 AT AT06718943T patent/ATE451381T1/de active
- 2006-01-19 PT PT06718943T patent/PT1856135E/pt unknown
- 2006-01-19 CN CN2006800026433A patent/CN101115761B/zh active Active
- 2006-01-19 DK DK06718943.1T patent/DK1856135T3/da active
- 2006-01-19 ES ES06718943T patent/ES2337496T3/es active Active
- 2006-06-14 US US11/453,731 patent/US7538108B2/en active Active
- 2006-10-05 US US11/539,074 patent/US7563892B1/en active Active
-
2007
- 2007-06-13 IL IL183890A patent/IL183890A/en active IP Right Grant
- 2007-06-14 MX MX2012002964A patent/MX346822B/es unknown
- 2007-08-14 NO NO20074179A patent/NO339146B1/no active Protection Beyond IP Right Term
-
2008
- 2008-03-13 HK HK08102972.0A patent/HK1108896A1/xx unknown
- 2008-11-10 US US12/268,218 patent/US7989448B2/en active Active
-
2010
- 2010-03-09 CY CY20101100218T patent/CY1109888T1/el unknown
-
2011
- 2011-06-30 US US13/174,091 patent/US8211888B2/en active Active
- 2011-07-08 JP JP2011152261A patent/JP2011236234A/ja active Pending
-
2012
- 2012-01-12 US US13/349,194 patent/US8211889B2/en active Active
- 2012-05-18 US US13/475,037 patent/US8476263B2/en active Active
-
2013
- 2013-06-04 US US13/909,858 patent/US8785437B2/en active Active
-
2014
- 2014-06-20 US US14/310,312 patent/US9266912B2/en active Active
-
2016
- 2016-01-13 US US14/995,027 patent/US9532998B2/en active Active
- 2016-11-23 US US15/360,025 patent/US20170291909A1/en not_active Abandoned
-
2018
- 2018-11-28 US US16/203,108 patent/US10577381B2/en active Active
-
2020
- 2020-03-02 US US16/806,541 patent/US20200270271A1/en active Pending
- 2020-04-28 NL NL301039C patent/NL301039I2/nl unknown
- 2020-05-08 LU LU00153C patent/LUC00153I2/fr unknown
- 2020-05-13 NO NO2020010C patent/NO2020010I1/no unknown
- 2020-05-19 HU HUS2000011C patent/HUS2000011I1/hu unknown
- 2020-05-19 FI FIC20200014C patent/FIC20200014I1/fi unknown
- 2020-06-04 LT LTPA2020507C patent/LTC1856135I2/lt unknown
- 2020-06-10 CY CY2020012C patent/CY2020012I1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2020507I1 (lt) | 2,4-Pirimidindiamino junginių provaistai ir jų panaudojimas | |
TW200734303A (en) | Organic compounds | |
ATE540041T1 (de) | Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon | |
MX2007005933A (es) | Compuestos de acetamida como fungicidas. | |
ATE430736T1 (de) | Pyridazinverbindung und deren verwendung | |
RS50660B (sr) | Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže | |
CL2013002895A1 (es) | Compuestos derivados de 7,8-dihidro-5h-pteridin-6-ona, utiles como intermediarios en la sintesis de compuestos derivados de pteridinona (divisional de la solicitud 3123-2005). | |
RS50629B (sr) | Amidni prolek gemcitabina, kompozicije i njihova primena | |
CY1110398T1 (el) | Ενωσεις για την αγωγη της δυσλιπιδαιμιας | |
MX2007003175A (es) | Medicamentos que contienen compuestos de carbonilo y su uso. | |
ATE526320T1 (de) | Antagonisten des vanilloidrezeptors vom subtyp 1 (vr1), und anwendungen davon | |
DE602006019732D1 (de) | Indolylmaleimidderivate | |
CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
TW200745039A (en) | Isotopically substituted pantoprazole | |
EA200801365A1 (ru) | Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины | |
TW200613279A (en) | New pesticides | |
ATE469134T1 (de) | Pharmazeutisch aktive diazepane | |
HK1128703A1 (en) | Neuroprotective compounds and uses thereof | |
DE602004009313D1 (de) | Organosiliziumverbindungen und deren verwendung | |
ITRE20040074A1 (it) | "profumatore per ambienti" | |
UA91210C2 (ru) | Пролекарства на основе соединений 2,4-пиримидиндиамина и их применение | |
TW200615274A (en) | Chemical compounds | |
JP2007505049A5 (de) | ||
ITRE20050141A1 (it) | "composizione insetticida solida sublimante" | |
UA13381S (uk) | Стіл «япі» |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1856135 Country of ref document: EP |